Throughout 2023, we at Parkinson’s News Today brought you coverage of the latest scientific advances and developments in treatments for Parkinson’s disease. Here we’ve compiled a list of the top 10 most-read stories published this past year. We look forward to continuing to share more developments with you in…
American football players at the professional level may be more likely to have symptoms similar to those seen in Parkinson’s disease, but the association remains inconclusive, a new study reports. The study, “Examination of parkinsonism in former elite American football players,” was published in Parkinsonism and Related…
More than three-quarters of people with early-onset Parkinson’s disease (EOPD) experience pain, according to a recent study conducted in Vietnam, with more severe pain reported by older patients and those with nonmotor symptoms such as depression, sexual dysfunction, and hallucinations. Additional studies with well-validated tools are needed to further…
One year of continuous subcutaneous (under-the-skin) apomorphine infusion (CSAI) reduced the severity of advanced Parkinson’s disease among patients across India, a study showed. Disease motor symptoms, as well as various Parkinson’s nonmotor symptoms like fatigue, pain, anxiety and depression, — along with quality of life — improved…
Alpha-synuclein, the protein that builds up into toxic clumps in Parkinson’s disease, may trigger neurons (nerve cells) to increase their production of new proteins, ultimately causing them to die, according to a recent study. “Parkinson’s disease has major impacts on quality of life for patients, but also for their…
Targeted ocular spectroscopy, a technology that allows real-time imaging of the back of the eye (or eye fundus) while observing how light interacts with specific structures in the retina, can help diagnose several eye and neurological conditions, including Parkinson’s disease, according to a recent study. The retina is the…
Factors such as exposure to environmental toxins and repeated blows to the head — all of which can be reduced with prevention efforts — may account for nearly 1 in 3 cases of Parkinson’s disease among men, and 1 in 4 among women. That’s according to a study of…
Researchers have figured out a new way to predict how brain cells communicate, which may have important implications for how deep brain stimulation (DBS) — a Parkinson’s disease treatment that involves implanting a device to stimulate targeted regions of the brain — is delivered. The ultimate goal, according to…
Alpha-synuclein — the protein that forms toxic clumps in the brains of people with Parkinson’s disease — may travel from enteroendocrine cells lining the gut to the brain through the vagus nerve, according to a study aiming to build on previous evidence of a gut-brain axis in Parkinson’s.
The U.S. Food and Drug Administration (FDA) has given Zydus Lifesciences a green light to conduct a Phase 2 trial of ZYIL1, an oral inhibitor of NLRP3 — a protein that’s linked to brain inflammation, or neuroinflammation — in people with Parkinson’s disease. The trial will evaluate the safety…
Get regular updates to your inbox.
